{"id":105365,"date":"2025-10-27T08:11:56","date_gmt":"2025-10-27T13:11:56","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?p=105365"},"modified":"2025-10-27T08:41:55","modified_gmt":"2025-10-27T13:41:55","slug":"un-nouvel-espoir-dans-le-domaine-des-traitements-cibles-contre-lhistiocytose","status":"publish","type":"post","link":"https:\/\/www.erdheim-chester.org\/fr\/new-hope-in-targeted-therapy-for-histiocytosis\/","title":{"rendered":"Un nouvel espoir dans le domaine des traitements cibl\u00e9s contre l'histiocytose"},"content":{"rendered":"<div>\n<p class=\"x_MsoNormal\"><span data-olk-copy-source=\"MessageBody\">Une nouvelle \u00e9tude publi\u00e9e par\u00a0<b>Centre de canc\u00e9rologie Memorial Sloan Kettering<\/b>\u00a0met en avant le potentiel de\u00a0<b>ulixertinib<\/b>, un m\u00e9dicament de th\u00e9rapie cibl\u00e9e qui bloque l'ERK, destin\u00e9 au traitement de certaines formes de\u00a0<b>histiocytose,<\/b>\u00a0notamment <b>Maladie d'Erdheim-Chester (ECD)<\/b>.<\/span><\/p>\n<p class=\"x_MsoNormal\">Dirig\u00e9e par le Dr Eli Diamond, membre du comit\u00e9 consultatif m\u00e9dical de l\u2019ECDGA, cette recherche marque une avanc\u00e9e prometteuse dans le traitement des troubles histiocytaires li\u00e9s \u00e0 la voie MAPK. Pour de nombreux membres de notre communaut\u00e9, \u00e0 l\u2019image de Joey, membre de l\u2019ECDGA dont le parcours ne cesse de nous inspirer, ces avanc\u00e9es scientifiques repr\u00e9sentent bien plus qu\u2019un simple progr\u00e8s clinique. Elles sont source d\u2019espoir.<\/p>\n<p class=\"x_MsoNormal\">Lisez l'article publi\u00e9 par le MSKCC :<br \/>\n<a title=\"https:\/\/www.mskcc.org\/news\/targeted-therapy-drug-ulixertinib-for-histiocytosis-blood\" href=\"https:\/\/www.mskcc.org\/news\/targeted-therapy-drug-ulixertinib-for-histiocytosis-blood\" target=\"_blank\" rel=\"noopener\" data-auth=\"NotApplicable\" data-linkindex=\"2\">https:\/\/www.mskcc.org\/news\/targeted-therapy-drug-ulixertinib-for-histiocytosis-blood<\/a><\/p>\n<p class=\"x_MsoNormal\">Consultez l'article technique complet sur <i>Cellule canc\u00e9reuse<\/i>:<br \/>\n<a title=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1535610825004064\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1535610825004064\" target=\"_blank\" rel=\"noopener\" data-auth=\"NotApplicable\" data-linkindex=\"3\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1535610825004064<\/a><\/p>\n<p class=\"x_MsoNormal\">\u00c0 l'ECDGA, nous sommes fiers de soutenir et de diffuser les travaux de recherche qui nous rapprochent de meilleurs soins, de r\u00e9ponses plus nombreuses et, un jour, d'un rem\u00e8de.<\/p>\n<p><em>L'Alliance mondiale contre la maladie d'Erdheim-Chester (ECDGA) ne fournit ni conseils m\u00e9dicaux, ni diagnostics, ni traitements. L'ensemble du contenu est pr\u00e9sent\u00e9 \u00e0 titre purement informatif. Veuillez consulter un professionnel de sant\u00e9 pour toute question d'ordre m\u00e9dical.<\/em><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Une nouvelle \u00e9tude men\u00e9e par le Memorial Sloan Kettering Cancer Center met en avant le potentiel de l'ulixertinib, un m\u00e9dicament de th\u00e9rapie cibl\u00e9e qui bloque l'ERK, dans le traitement de certaines formes d'histiocytose, notamment la maladie d'Erdheim-Chester (ECD).<\/p>","protected":false},"author":14,"featured_media":105366,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[51],"tags":[375,2599,5100,5103,5107,102,5104,5105,5106,3473,5101,4254,5108,5102,4957],"class_list":["post-105365","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-ecdawareness","tag-elidiamond","tag-erdheim-chesterdisease","tag-erkinhibitor","tag-histiocyticdisorders","tag-histiocytosis","tag-mapkpathway","tag-memorialsloankettering","tag-precisionmedicine","tag-rarebloodcancer","tag-rarecancer","tag-rarediseaseresearch","tag-researchbreakthrough","tag-targetedtherapy","tag-ulixertinib"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/posts\/105365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/comments?post=105365"}],"version-history":[{"count":0,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/posts\/105365\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/media\/105366"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/media?parent=105365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/categories?post=105365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/tags?post=105365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}